Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.
Non Small Cell Lung Cancer Metastatic
DRUG: Pembrolizumab in Combination with Plinabulin and Docetaxel
ORR, objective response rate, the proportion of participants who have achieved a confirmed complete response (CR) or partial response (PR), which is assessed according to RECIST 1.1 criteria., through study completion, an average of 1 year
PFS, progression-free survival, the time from treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first., through study completion, an average of 1 year
OS, overall survival, the time from allocation to the date of death due to any cause., through study completion, an average of 1 year|DOR, duration of response, the time from the first documented evidence of CR or PR until PD or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, through study completion, an average of 1 year|Adverse events (AEs), Safety endpoints, through study completion, an average of 1 year
A Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemotherapy.